Gyre Therapeutics, Inc. Common Stock GYRE
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-19T20:26:18.644Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-07-16
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-19T20:19:12.854783844Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-19T20:26:04.431939+00:00
Gyre Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | 5.18 | 161.3% | 42.2% | |||
| 35Δ | 5.46 | 150.4% | 37.5% | |||
| 40Δ | 5.74 | 139.4% | 32.8% | |||
| 45Δ | 6.02 | 128.5% | 28.1% | |||
| 50Δ | 6.29 | 117.6% | 23.4% | |||
| 55Δ | 6.57 | 106.6% | 18.6% | |||
| 60Δ | 6.85 | 95.7% | 13.9% | |||
| 65Δ | 7.13 | 84.8% | 9.2% | |||
| 70Δ | 7.40 | 73.8% | 4.5% | |||
| 75Δ | ||||||
| 80Δ | 4.19 | 167.7% | 48.5% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.18
- IV
- 161.3%
- B/E move
- 42.2%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.46
- IV
- 150.4%
- B/E move
- 37.5%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.74
- IV
- 139.4%
- B/E move
- 32.8%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.02
- IV
- 128.5%
- B/E move
- 28.1%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.29
- IV
- 117.6%
- B/E move
- 23.4%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.57
- IV
- 106.6%
- B/E move
- 18.6%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.85
- IV
- 95.7%
- B/E move
- 13.9%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.13
- IV
- 84.8%
- B/E move
- 9.2%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.40
- IV
- 73.8%
- B/E move
- 4.5%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 4.19
- IV
- 167.7%
- B/E move
- 48.5%
- Pseudo strike
- IV
- B/E move
Options history
History unavailable
Biotechnology
HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is…
More →HELP
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health…
More →HOWL
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapies designed to boost the body's immune system for the treatment of cancer. The company is headquartered…
More →HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is…
More →HUMA
Description unavailable
More →IBRX
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy.
More →